Livzon Pharmaceutical Group Inc. (Livzon) obtained a “novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No. 2021L90001, 2021L90002, 2021L90003). V-01 is to prevent diseases caused by novel coronavirus infection.
V-01 is an innovative novel coronavirus recombinant protein vaccine developed by Livzon and the Institute of Biophysics, Chinese Academy of Sciences. V-01 belongs to the technical route of recombinant protein vaccine among the other five technical routes of the novel coronavirus vaccine, which can be transported and stored at 2-8°C.
During the development of V-01, Shanghai Medicilon Inc. (Medicilon) undertook the drug safety evaluation. Since the establishment of the V-01 project, Medicilon has relied on a strong technical team and R&D platform to gather experts, technology, equipment and other resources in order to shorten the R&D time.
The development of a novel coronavirus vaccine is a battle against time and the virus. The colleagues of Medicilon who participated in the development of V-01 worked overtime and overcome the difficulties during the development continuously in 4 months to ensure that every experiment is carried out on time and every analysis results are provided on time.
Medicilon congratulates Livzon on its milestone and wishes V-01 will be launched soon to help prevent and control the novel coronavirus epidemic. Medicilon is proud to be a part to contribute the research and development of the novel coronavirus vaccine.
Livzon Pharmaceutical Group Inc., established in January 1985 with registered capital of RMB 953 million, is a comprehensive pharmaceutical group company integrating pharmaceutical R&D, production and sales, with more than 9,000 employees. In 1993, Livzon A and B shares have been listed. In 2014, the company completed the conversion from B shares to H shares, making it one of the few listed pharmaceutical companies with A+H shares in the capital market.
Livzon is committed to ensuring effective, safe and stable products. The Group’s pharmaceutical enterprises have established a sound quality management system. As of 2018, Total 31 production lines of 4 pharmaceutical subsidiaries have passed GMP certification. 28 varieties of 4 API companies have passed GMP certification and other 11 varieties have passed veterinary medicine GMP certification. 15 API varieties have passed the field inspection of international certification and obtained 20 international certification certificates.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 700 clients globally. Medicilon is proud to contribute to human health in the globe.